연구동향 분석
박사

공통데이터모델에 기반한 비타민 K 비의존성 경구항응고제의 효과 및 안전성 분석

강동윤 2019년

논문상세정보
인용/피인용
' 공통데이터모델에 기반한 비타민 K 비의존성 경구항응고제의 효과 및 안전성 분석' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • 능동적약물감시, 공통데이터모델, 비타민 K 비의존성 경구항응고제, 와파린, 약물안전성평가, 약물역학
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
3,950 0

0.0%

' 공통데이터모델에 기반한 비타민 K 비의존성 경구항응고제의 효과 및 안전성 분석' 의 참고문헌

  • 의료법 제21조 1항
  • Yuan H, Ali MS, Brouwer ES, et al. Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). Clin Pharmacol Ther 2018;104(2):239-41. doi: 10.1002/cpt.1086
  • Young D. FDA's sentinel network: a monumental task. Am J Health Syst Pharm 2007;64(8):800-1. doi: 10.2146/news070036
  • Yap SH, Ng YP, Roslan A, et al. A comparison of dabigatran and warfarin for stroke prevention in elderly Asian population with nonvalvular atrial fibrillation: An audit of current practice in Malaysia. Med J Malaysia 2017;72(6):360-64.
  • Yamashita T, Koretsune Y, Yang Y, et al. Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation- An ENGAGE AF-TIMI 48 Subanalysis. Circ J 2016;80(4):860-9. doi: 10.1253/circj.CJ-15-1082 [published Online First: 2016/02/19]
  • Wong KS, Hu DY, Oomman A, et al. Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. Stroke 2014;45(6):1739-47. doi: 10.1161/STROKEAHA.113.002968 [published Online First: 2014/04/26]
  • Weng C, Li Y, Ryan P, et al. A Distribution-based Method for Assessing The Differences between Clinical Trial Target Populations and Patient Populations in Electronic Health Records. Appl Clin Inform 2014;5(2):463-79. doi: 10.4338/Aci-2013-12-Ra-0105
  • Volterrani M, Iellamo F, Alberto C, et al. NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. Intern Emerg Med 2018;13(7):1069-75. doi: 10.1007/s11739-018-1896-9
  • Thompson CA. Oral direct factor Xa inhibitor gets FDA's OK. Am J Health Syst Pharm 2011;68(16):1467. doi: 10.2146/news110054
  • The importance of pharmacovigilance. Safety monitoring of medicinal products. Geneva: World Health Organization 2002.
  • The Sentinel Initiative - A National Strategy for Monitoring Medical Product Safety: Department of Health and Human Services, Food and Drug Administration.
  • The Observational Medical Outcomes Partnership (OMOP) CDM: OHDSI –Observational Health Data Sciences and Informatics; [Available from: https://www.ohdsi.org/data-standardization/the-common-data-model/.
  • Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113(5):359-64.
  • Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368(14):1272-4. doi: 10.1056/NEJMp1302834 [published Online First: 2013/03/15]
  • Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med 2016;375(23):2293-97. doi: 10.1056/NEJMsb1609216
  • Senoo K, Lau YC, Dzeshka M, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation - meta-analysis. Circ J 2015;79(2):339-45. doi: 10.1253/circj.CJ-14-1042
  • Schneeweiss S, Wang PS, Avorn J, et al. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 2003;38(4):1103-20. [published Online First: 2003/09/13]
  • Sandhu RK, Bakal JA, Ezekowitz JA, et al. Risk stratification schemes, anticoagulation use and outcomes: the risk--treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart 2011;97(24):2046-50. doi: 10.1136/heartjnl-2011-300901 [published Online First: 2011/11/15]
  • Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0
  • Royall BW. International aspects of drug monitoring. Role of the World Health Organization. WHO Chron 1971;25(10):445-51.
  • Rodriguez-Bernal CL, Hurtado I, Garcia-Sempere A, et al. Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. Front Pharmacol 2017;8:63. doi: 10.3389/fphar.2017.00063
  • Reisinger SJ, Ryan PB, O'Hara DJ, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J Am Med Inform Assn 2010;17(6):652-62. doi: 10.1136/jamia.2009.002477
  • Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173(6):676-82. doi: 10.1093/aje/kwq433 [published Online First: 2011/02/19]
  • Psaty BM, Breckenridge AM. Mini-Sentinel and regulatory science--big data rendered fit and functional. N Engl J Med 2014;370(23):2165-7. doi: 10.1056/NEJMp1401664
  • Propensity score matching method의 소개
    이동규 Anesth Pain Med (11):130-48 [2016]
  • Platt R, Wilson M, Chan KA, et al. The new Sentinel Network--improving the evidence of medical-product safety. N Engl J Med 2009;361(7):645-7. doi: 10.1056/NEJMp0905338
  • Platt R, Madre L, Reynolds R, et al. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 2008;17(12):1175-82. doi: 10.1002/pds.1668
  • Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:1-8. doi: 10.1002/pds.2343
  • Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100. doi: 10.1378/chest.10-0134 [published Online First: 2010/03/20]
  • Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91. doi: 10.1056/NEJMoa1009638
  • Park BJ, Sung JH, Park KD, et al. Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database. Seoul National University 2003:19 - 52.
  • Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012;19(1):54-60. doi: 10.1136/amiajnl-2011-000376 [published Online First: 2011/11/01]
  • Noseworthy PA, Yao X, Abraham NS, et al. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest 2016;150(6):1302-12. doi: 10.1016/j.chest.2016.07.013
  • Mueller S, Groth A, Spitzer SG, et al. Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset. Pragmat Obs Res 2018;9:1-10. doi: 10.2147/POR.S156521
  • Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 2015;386(9990):281-91. doi: 10.1016/S0140-6736(15)60243-4
  • Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110(9):1042-6. doi: 10.1161/01.CIR.0000140263.20897.42
  • Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin A propensity score matched analysis. Thromb Haemostasis 2016;116(5):975-86. doi: 10.1160/Th16-05-0403
  • Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72. doi: 10.1378/chest.09-1584 [published Online First: 2009/09/19]
  • Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57(2):173-80. doi: 10.1016/j.jacc.2010.09.024 [published Online First: 2010/11/30]
  • Li WH, Huang D, Chiang CE, et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project. Clin Cardiol 2017;40(4):222-29. doi: 10.1002/clc.22649
  • Lee SR, Choi EK, Han KD, et al. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. PLoS One 2017;12(12):e0189495. doi: 10.1371/journal.pone.0189495 [published Online First: 2017/12/21]
  • Lee S, Han J, Park RW, et al. Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance. Drug Saf 2019 doi: 10.1007/s40264-018-0767-7
  • Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016;353:i3189. doi: 10.1136/bmj.i3189
  • Lai CL, Chen HM, Liao MT, et al. Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. J Am Heart Assoc 2017;6(4) doi: 10.1161/JAHA.116.005362
  • Kohsaka S, Murata T, Izumi N, et al. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Curr Med Res Opin 2017;33(11):1955-63. doi: 10.1080/03007995.2017.1374935
  • Ko YJ, Kim S, Park K, et al. Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016. Journal of Korean Medical Science 2018;33(23) doi: UNSP e163 10.3346/jkms.2018.33.e163
  • Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37(38):2893-962. doi: 10.1093/eurheartj/ehw210
  • Kimura T, Matsushita Y, Yang YH, et al. Pharmacovigilance systems and databases in Korea, Japan, and Taiwan. Pharmacoepidemiol Drug Saf 2011;20(12):1237-45. doi: 10.1002/pds.2244
  • Kim HS, Lee S, Kim JH. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J Korean Med Sci 2018;33(34):e213. doi: 10.3346/jkms.2018.33.e213
  • Kang DY, Ahn KM, Kang HR, et al. Past, present, and future of pharmacovigilance in Korea. Asia Pac Allergy 2017;7(3):173-78. doi: 10.5415/apallergy.2017.7.3.173
  • Joung B, Lee JM, Lee KH, et al. 2018 Korean Guideline of Atrial Fibrillation Management. Korean Circ J 2018;48(12):1033-80. doi: 10.4070/kcj.2018.0339
  • Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998;5(3):305-14. doi: 10.1136/jamia.1998.0050305
  • International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser 1972;498:1-25.
  • Huang YL, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. Drug Saf 2014;37(8):581-96. doi: 10.1007/s40264-014-0194-3 [published Online First: 2014/07/16]
  • How ARIA Analyses Have Been Used by FDA [Available from: https://www.sentinelinitiative.org/drugs/how-aria-analyses-have-been-used-fda accessed Jan 25th 2019.
  • Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44(7):1891-6. doi: 10.1161/STROKEAHA.113.000990 [published Online First: 2013/06/08]
  • Hohnloser SH, Basic E, Nabauer M. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol 2017;106(8):618-28. doi: 10.1007/s00392-017-1098-x
  • Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27(8):949-53. doi: 10.1093/eurheartj/ehi825
  • Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf 2006;29(5):385-96. doi: 10.2165/00002018-200629050-00003
  • Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc 2015;4(1):e001486. doi: 10.1161/JAHA.114.001486
  • Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92. doi: 10.1056/NEJMoa1107039
  • Graham DJ, Reichman ME, Wernecke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016;176(11):1662-71. doi: 10.1001/jamainternmed.2016.5954
  • Goto S, Zhu J, Liu L, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J 2014;168(3):303-9. doi: 10.1016/j.ahj.2014.06.005 [published Online First: 2014/09/01]
  • Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104. doi: 10.1056/NEJMoa1310907
  • Galson SaGS. Real-World Evidence to Guide the Approval and Use of New Treatments. NAM Perspectives Discussion Paper. Washington, DC: National Academy of Medicine 2016.
  • Fu W, Guo H, Guo J, et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. J Cardiovasc Med (Hagerstown) 2014;15(12):873-9. doi: 10.2459/JCM.0000000000000206
  • FDA drug safety communication: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate), 2011.
  • Establishment of a National Common Data Model linking hospital EMRs: Ministry of Food and Drug Safety, 2017.
  • Emren SV, Zoghi M, Berilgen R, et al. Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study. Bosn J Basic Med Sci 2018;18(2):185-90. doi: 10.17305/bjbms.2017.2279
  • Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353(10):1028-40. doi: 10.1056/NEJMra044440
  • Development of a common data model for adverse drug reactions using hospital EMR: Ministry of Food and Drug Safety, 2017.
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51. doi: 10.1056/NEJMoa0905561
  • Coleman CI, Peacock WF, Bunz TJ, et al. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke 2017;48(8):2142-49. doi: 10.1161/STROKEAHA.117.017474
  • Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Pub Health 2007;40(4):278 - 84.
  • Cho MS, Yun JE, Park JJ, et al. Outcomes After Use of Standard- and Low-Dose Non-Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke 2019;50(1):110-18. doi: 10.1161/Strokeaha.118.023093
  • Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014;111(5):789-97. doi: 10.1160/TH13-11-0948
  • Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA 2017;318(13):1250-59. doi: 10.1001/jama.2017.13883
  • Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. J Am Coll Cardiol 2016;68(13):1389-401. doi: 10.1016/j.jacc.2016.06.062
  • Cha MJ, Choi EK, Han KD, et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke 2017;48(11):3040-48. doi: 10.1161/STROKEAHA.117.018773
  • Carmo J, Moscoso Costa F, Ferreira J, et al. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016;116(4):754-63. doi: 10.1160/TH16-03-0203
  • Bjorck S, Palaszewski B, Friberg L, et al. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 2013;44(11):3103-8. doi: 10.1161/STROKEAHA.113.002329
  • Berger M, Daniel G, Frank K, et al. A Framework for Regulatory Use of Real-World Evidence2017.
  • Ball R, Robb M, Anderson SA, et al. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance. Clin Pharmacol Ther 2016;99(3):265-8. doi: 10.1002/cpt.320
  • Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med 2011;30(11):1292-301. doi: 10.1002/sim.4200 [published Online First: 2011/02/22]
  • Alonso A, MacLehose RF, Chen LY, et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart 2017;103(11):834-39. doi: 10.1136/heartjnl-2016-310586
  • Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857. doi: 10.1136/bmj.h1857
  • Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology 2017;152(5):1014-22 e1. doi: 10.1053/j.gastro.2016.12.018